Human Insulin Drugs and Delivery Device Market Size & Share | 2022
Market Overview
The Human Insulin Drugs and Delivery Devices Market is expected to register a CAGR greater than 3% over the forecast period, 2022–2027.
Diabetes mellitus is considered a risk factor for increasing COVID-19. During the COVID-19 pandemic, tight control of glucose levels and prevention of diabetes complications might be crucial in patients with diabetes mellitus to keep susceptibility low and to prevent severe courses of COVID-19. COVID-19 affects glucose metabolism, mainly in patients with diabetes due to this frequent usage of insulin drugs and delivery devices market increased.
Diabetes is generally considered a lifestyle-related disease. Over time, with the increase in population around the world, the incidences of the disease have increased outrageously. Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10–25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. Insulin Drugs and delivery devices are necessary for type-1 diabetes patients because their body doesn’t produce insulin internally, type-2 diabetes patients also need insulin, particularly those who have difficulty controlling their diabetes with oral medications.
Scope of the Report
The Market is segmented by Drug Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), by Device Type (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments.
Comments
Post a Comment